Publications by authors named "Yu Liu Ho"
Evaluation of the Effect of Momelotinib on Cardiac Repolarization: A Thorough QT Study.
Clin Pharmacol Drug Dev
January 2025
A randomized, partially blinded, placebo-controlled, crossover study in 48 healthy adults assessed the effect of momelotinib on the heart rate-corrected QT interval (QTc) using the Fridericia formula (QTcF). QTc was evaluated for momelotinib 200 mg (therapeutic dose), momelotinib 800 mg (supratherapeutic dose), moxifloxacin 400 mg (positive control), and placebo. Pharmacokinetic profiles of momelotinib and its active metabolite M21 were evaluated.
View Article and Find Full Text PDFArticle Synopsis
- Myelofibrosis is a chronic condition that involves bone marrow issues, spleen enlargement, anemia, and can reduce life expectancy to about 6 years after diagnosis.
- Current treatments like JAK inhibitors can help with symptoms but often worsen anemia, which negatively affects survival rates; however, momelotinib is a new JAK inhibitor that also improves anemia.
- Momelotinib works by targeting both the JAK-STAT signaling pathway and the ACVR1 receptor, leading to reduced spleen size and better blood cell production, with a recommended dose of 200 mg taken once daily.
Article Synopsis
- Momelotinib, an approved treatment for myelofibrosis in adults with anemia, was studied for drug-drug interactions (DDIs) with different inhibitors and inducers affecting its metabolism, specifically looking at the impact of medications like ritonavir and rifampin.
- The study found that while coadministration with ritonavir and rifampin did increase momelotinib and its metabolite M21 exposure, these changes were not clinically significant.
- Momelotinib did not impact the metabolism of certain drugs, but it significantly altered the levels of rosuvastatin, indicating that monitoring and possible dose adjustments may be necessary for patients taking these medications together.